Dr. Kenneth Pienta Laboratory

Clinical Trials

Dr. Pienta will see patients with high risk localized prostate cancer and advanced prostate cancer at the  Sidney Kimmel Comprehensive Cancer Center and the Brady Urological Institute at Johns Hopkins Hospital.


Current clinical trials include:

Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 – Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy E2809

Psychopharmacology of psilocybin in cancer patients

Phase I safety study of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies

A phase 1, Open-label, Multicenter, multidose, Dose-escalation Study of BMS-936558/MDX-1106 in Subjects with Selected Advance or Recurrent Malignancies

A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb 004, a Humanized Monoclonal Antibody, in Subjects with Solid Tumors

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

A Phase I study of the mTOR inhibitor Temsirolimus in combination with the HDAC inhibitor Vorinostat in patients with metastatic prostate cancer .

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men with Castration Resistant Prostate Cancer

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Advanced Solid Tumors.

Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy

A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects with Advanced Prostate Cancer.

Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA based PET in Patients with Advanced Prostate Cancer

A phase I/IIa study of safety and efficacy of Alpharadin® with docetaxel in patients with bone metastases from castration-resistant prostate cancer

A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration resistant prostate cancer

A Phase II Trial of STA-9090 in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Pretreated with Docetaxel Based Chemotherapy

An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors

Efficacy and Safety of oral Kanglaite (KLTc) Gelcap in Men with Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc Gelcap (3 or 6 capsules four times/day) on Prostate Specific Antigen (PSA) Doubling Time Among Men with Rising PSA Levels after Definitive Local Therapy for Prostate Cancer

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen.

Phase I/II study of safety and efficacy of Muscadine Plus (MPX) in men with prostate cancer: A randomized, double-blind, placebo-controlled study of the effects of two doses of MPX capsule on rising prostate-specific antigen in men following initial therapy for prostate cancer

Evaluation of PSMA-based PET as an imaging biomarker of primary prostate cancer

A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol and daily genistein (G-2535) versus placebo in men with early stage prostate cancer undergoing prostatectomy

A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT 888 For Patients With Metastatic Castration-Resistant Prostate Cancer (NCI# 9012)

A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors

A neoadjuvant immunologic study of androgen deprivation therapy combined with a GM-CSFâ??secreting allogeneic prostate cancer vaccine and low-dose cyclophosphamide in men with high-risk localized prostate cancer undergoing radical prostatectomy

A Phase II Study of Bipolar Androgen-based Therapy for Men with Androgen Ablation Naïve Recurrent Prostate Cancer

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion